In this interview to Nivedita Mookerji of Business Standard, Dr Amita Gupta, who's also a professor of infectious diseases at the Johns Hopkins School of Medicine, talks about 2022 being more of the same, how the year will have more waves and that Covid will never go away. She explains how the Johns Hopkins Covid dashboard became a household name, while highlighting the weakness in the health infrastructure and data systems in many countries including in India. According to Dr Gupta, Covid19 should be seen as a wakeup call to improve things.
Getting more shots into more arms is also crucial for ensuring that India's economy continues to grow in a sustained manner. We have done a reality check. Watch the video
What happened to ambulance sales during the pandemic? Business Standard looked at some of the available data, and the takeaways were quite surprising. Watch the video
Over 22 million Indians lost their jobs in the months of April across the country due to the second wave of Covid-19. Watch Mahesh Vyas, Head, Centre for Monitoring Indian Economy, talk about the impact of coronavirus pandemic on the livelihood of citizens in this video
AIIMS director Randeep Guleria said that as the number of recovered patients rises, clinics have to be developed to deal with the treatment of symptoms which persist beyond the disease. He said there was now a better understanding of post-Covid acute syndrome which can continue 8 to 12 weeks and long Covid which can occur if symptoms continue beyond 12 weeks. Watch this video to understand the post-Covid complications and treatment options as explained by the AIIMS chief.
Coronavirus updates: A decision on the next phase of Covid-19 vaccination was taken at a meeting of the Union Cabinet under the chairmanship of Prime Minister Narendra Modi on February 24. Who is eligible in the second round of vaccination and what are the charges, if any? Will there be a choice in the vaccine? The video answers all your queries in a quick time.
Ministry of Health and Family Welfare has identified a list of critical medical equipment and has requested the NPPA to ensure availability of the same in the country
Serum Institute of India CEO Adar Poonawalla said that the coronavirus vaccine will be distributed initially in India and then the company will look at Covax countries, which are mainly in Africa. Serum Institute of India (SII) is conducting clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate in India. Watch the full interview.
Unless quick steps are taken to clear surplus milk and milk product stocks in the country, the coming flush season will spell bad news for milk farmers, especially small and marginal ones
Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019
The airline posted a pre tax loss of Rs 2842.6 crore in Q1FY21 against a pre tax profit of Rs 1509.4 crore in the same quarter of the last year
The news of the former President testing positive for Covid-19 comes on a day when India reported a spike of 62,064 fresh cases on Monday taking the total tally to 2,215,074
74% rural Indians satisfied with govt's setps fight pandemic, 78% happy with measures taken by their state govt, says Lokniti-CSDS study
Universities and schools across the country have been closed since March 16 when the Centre announced a countrywide classroom shutdown as part of measures to contain the Covid-19 outbreak
Researchers, including one of Indian-origin, have identified a pattern of longer-term symptoms likely to be experienced by people who were hospitalised with the Covid-19 infection.
BJP president J P Nadda launched a scathing attack on the TRS government in Telangana over handling of the Covid-19 pandemic, accusing it of 'negligence' and being in a state of 'slumber'
Director General of Assam Police Bhaskar Jyot Mahanta tested positive for Covid-19 on Monday, officials said.
As many as 1,256 COVID-19 cases and 10 deaths were reported in Telangana on Sunday, taking the total number of cases to 80,751 in the state.
The company had also announced separate plans to raise at least $268 million through the sale and leaseback of planes and other assets
German biotech CureVac B.V., which is in early stages of testing its coronavirus vaccine, said on Monday it expects to raise up to $213 million in its U.S. initial public offering (IPO).